63 KanterJ.AbboudM
But percentage increases from a low baseline can be misleading
A phase 2 randomised placebo controlled double-blind trial (IIH:Pressure trial) demonstrated the efficacy of exenatide at significantly reducing ICP, as measured using highly accurate telemetric ICP monitors, in people with IIH [19]
20, the FDA announced that the agency had approved Zepbound to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Most chose to drop it or never offered it at all
GLP-1 medical weight loss (semaglutide, tirzepatide, retatrutide), peptide therapy (BPC-157, Sermorelin, Tesamorelin, NAD+), hormone optimization, Korean-inspired facials, Botox and Dysport, dermal fillers, RF microneedling, lasers, IV therapy